Induction Immunosuppressive Therapies in Renal Transplantation

Steven Gabardi, Pharm.D., BCPS; Spencer T. Martin, Pharm.D., BCPS; Keri L. Roberts, Pharm.D.; Monica Grafals, M.D.


Am J Health Syst Pharm. 2011;68(3):211-218. 

In This Article

Currently Available Induction Therapies

Only a small number of immunosuppressants are used for induction therapy, including monoclonal antibodies (muromonab-CD3, basiliximab, daclizumab, and alemtuzumab) and polyclonal antibodies (antithymocyte globulin [equine] and antithymocyte globulin [rabbit]). These agents are further differentiated as depleting proteins (alemtuzumab, antithymocyte globulins, and muromonab-CD3) or nondepleting proteins (basiliximab and daclizumab), depending on their ability to deplete T cells.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.